Selected article for: "lymphocyte count and secondary primary efficacy"
Author: Marty, Francisco M; Chemaly, Roy F; Mullane, Kathleen M; Lee, Dong-Gun; Hirsch, Hans H; Small, Catherine B; Bergeron, Anne; Shoham, Shmuel; Ljungman, Per; Waghmare, Alpana; Blanchard, Elodie; Kim, Yae-Jean; McKevitt, Matt; Porter, Danielle P; Jordan, Robert; Guo, Ying; German, Polina; Boeckh, Michael; Watkins, Timothy R; Chien, Jason W; Dadwal, Sanjeet S
Title: A Phase 2b, Randomized, Double-blind, Placebo-Controlled Multicenter Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of Presatovir in Hematopoietic Cell Transplant Recipients with Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract
  • Document date: 2019_12_3
    • ID: sl45z4i0_17
    Snippet: The safety population included patients who received ≥1 dose of study drug. The efficacy population included safety population patients with quantifiable RSV viral load on day 1. Primary and secondary efficacy endpoints were analyzed in the efficacy population and post hoc in subgroups defined by supplemental oxygen use, ribavirin use, duration of RSV symptoms, graft-vshost disease (GVHD), lymphocyte count, and time from HCT to RSV infection on.....
    Document: The safety population included patients who received ≥1 dose of study drug. The efficacy population included safety population patients with quantifiable RSV viral load on day 1. Primary and secondary efficacy endpoints were analyzed in the efficacy population and post hoc in subgroups defined by supplemental oxygen use, ribavirin use, duration of RSV symptoms, graft-vshost disease (GVHD), lymphocyte count, and time from HCT to RSV infection on day 1.

    Search related documents:
    Co phrase search for related documents
    • efficacy population and safety population: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • efficacy population and safety population patient: 1, 2, 3, 4, 5
    • efficacy population and study drug: 1, 2
    • HCT time and rsv infection: 1, 2
    • HCT time and study drug: 1
    • rsv infection and secondary primary efficacy: 1
    • rsv infection and study drug: 1, 2
    • safety population and secondary primary efficacy: 1
    • safety population and secondary primary efficacy endpoint: 1
    • safety population and study drug: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • safety population and study drug dose receive: 1
    • secondary primary efficacy and study drug: 1